The available novel diabetes therapies and their impact on cardiovascular and cardiometabolic risk reduction are discussed by guests Chris Memering, MSN, RN, CDCES, BC-ADM, FADCES, and Sun Kim, MD. A particular emphasis on GLP-1 receptor agonists, and the patients for whom they are guideline recommended, as well as ongoing research are also covered.
CE LINK: pcna.net/podcast/novel-diabetes-therapies-in-cvd-risk-reduction
GLP-1 RAs: An updated reivew of head-to-head clinical studies: https://pubmed.ncbi.nlm.nih.gov/33767808/
GLP1-RAs: CV benefts & mechanisms of action (Ussher & Drucker): https://pubmed.ncbi.nlm.nih.gov/36977782/
GLP-1 & Underlying Beneficial Actions in Alzheimer's disease, Hypertension, & NASH: ttps://pubmed.ncbi.nlm.nih.gov/34552561/
Incretins & microvascular complications of diabetes: https://pubmed.ncbi.nlm.nih.gov/37597048/
Management of Type 2 Diabetes 2022. A Consensus Report by ADA, EASD. doi: 10.2337/dci22-0034.
ADA Standards of Care in Diabetes 2023. https://diabetesjournals.org/care/issue/46/Supplement_1
AACE Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm--2023 Update.
https://www.endocrinepractice.org/article/S1530-891X(23)00034-4/fulltext
Cardio-renal-metabolic connection: a review of the Evidence. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391899/pdf/12933_2023_Article_1937.pdf
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
